Company profile
UK company 05969271, incorporated on 17 October 2006.
Tissue Regenix Group PLC is a UK company with status active founded in 2006 based in Yorkshire and the Humber.
Company number 05969271
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
The company's patented decellularisation ('dCELL®') Technology removes DNA and other cellular material from tissue leaving intact an inert acellular matrix upon which the patients cells can repopulate. The potential applications of dCELL® are diverse and address critical clinical needs such as; wound care, heart valve replacement and knee repair. Spun out of the University of Leeds in 2006, Tissue Regenix commercialise upon research undertaken by our higher education and research partners around the world. Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012. In early 2016, Tissue Regenix entered its first joint venture establishing GBM-V , a Tissue Bank in Rostock, Germany, granting them the first licence for the production of dCELL® heart valves, and strengthening its presence within Europe.
The dCELL® process involves the creation of biological scaffolds which are essentially inert. By removing DNA and cellular material from biological tissues, the patient's cells can repopulate and colonize creating new, like for like tissue, which is recognized and accepted by the body, significantly reducing the risk of rejection, and stimulating a natural healing process.
